By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Aino Health AB (publ): interim report january-september 2024
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Health

Aino Health AB (publ): interim report january-september 2024

GlobeNews Wire
Last updated: 15/11/2024 3:53 PM
GlobeNews Wire
Share
4 Min Read
Aino Health AB (publ): interim report january-september 2024
SHARE
Aino Health AB (publ): interim report january-september 2024

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.

Aino reveals the main reasons for absence at work

January – September 2024

  • Net sales were KSEK 17 941 (17 605)
  • Profit/loss after financial items was KSEK -6 464 (-6 812)
  • Earnings per share were SEK-0,1 (-0,2)

July – September 2024

  • Net sales were KSEK 5 712 (5 633)
  • Profit/loss after financial items was KSEK -1 504 (-1 215)
  • Earnings per share were SEK -0.0 (-0.0)

During the third quarter, we continued to strengthen our market position by securing new business and expanding our network of customers. Market activity has been promising, and we see a clear demand for our services and solutions. By combining our expertise with our partnerships, we have been able to create new opportunities for growth and success. For the coming year, we see opportunities for growth in sales, earnings and cash flow, driven both by the new business we have already secured and the increased market activity. This growth is a result of our dedicated work and the long-term investments we make to create value for our customers and partners.

We are also incredibly proud that our ground-breaking data insights report on sickness absence has received such a positive response. This regular report, available on our website, lists, among other things, the top 10 causes of sickness absence and offers concrete advice on how to prevent them. We recognise that these insights help our customers to understand the underlying factors of sickness absence, giving them the tools they need to promote a healthy and productive work environment.

Our strategy is to deliver solutions that not only improve our customers’ productivity, but also strengthen relationships within their organisations. We are committed to investing in the success of our people and our customers. Our work on data analytics and insights is a cornerstone of this strategy and we are confident that our solutions will contribute to long-term sustainability and efficiency for our customers.

Click here to read the report!

The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of Jyrki Eklund, CEO and President of Aino Health AB, at 08.30 AM CET on november 15, 2024.

For more information
Jyrki Eklund
CEO Aino Health
Phone: +358 40 042 4221
jyrki.eklund@ainohealth.com

Aino Health AB (publ) is listed on Nasdaq Stockholm First North Growth Market (Ticker: AINO).

Certified adviser
Carnegie Investment Bank AB (publ)
For more information see: https://investors.ainohealth.com/certified-adviser/

About Aino Health (publ)
Aino Health is the leading provider of Software as a Service solutions in Corporate Health Management.
The company’s complete system of SaaS platforms and services reduces sick leave, lowers related costs and improves business outcomes through increased productivity and employee engagement by making health, well-being and safety an integral part of daily work. For more information visit ainohealth.com.

  • Aino_Q3_2024_ENG

You Might Also Like

NextGenInnov8 Announces Publication of Case Study on Young Innovator Aditya Pachpande, Aligned with India’s Push for STEM and Innovation Education

HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences

IOC President Bach in Italy to mark one year to go until Olympic Winter Games Milano Cortina 2026

Huawei: Helping Carriers Reshape Business, Infrastructure, and O&M with AI

Bybit Web3 Wallet Integrates Tonstakers: The First of Its TON Staking Offerings to Expand DeFi Opportunities

TAGGED:absenceainoanycasediscrepancydocumentenglishHealthinterimjanuaryjanuary-septembermainoriginalprevailreasonsreportrevealsseptemberswedishtranslationuncategorizedwillwork

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
Next Article AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
Business 09/06/2025
KBRA Releases Research  Private Credit: Business Development Company (BDC) Ratings Compendium: First-Quarter 2025
KBRA Releases Research Private Credit: Business Development Company (BDC) Ratings Compendium: First-Quarter 2025
Business 09/06/2025
RP1 Launches the Worlds First Metaverse Browser
RP1 Launches the Worlds First Metaverse Browser
Business 09/06/2025
ATLANTIC-ACM Announces 2025 U.S. Business Connectivity Service Provider Excellence Awards
ATLANTIC-ACM Announces 2025 U.S. Business Connectivity Service Provider Excellence Awards
Business 09/06/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?